We’ve been around the preemption block a few times – we know what happens when the mainstay claim in prescription medical product liability litigation, that being inadequate warnings, gets preempted. We first saw it in DTP vaccine litigation. We made a little headway with preemption and plaintiffs responded with “design’ claims based on non-FDA-approved formulations. It took the Vaccine Act to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to We Don't Recall
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account